Adding an Insulin-Sensitizing Medication to Depression Treatment for People Who Are Depressed and Overweight

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00834652
Recruitment Status : Completed
First Posted : February 3, 2009
Results First Posted : February 28, 2018
Last Update Posted : February 28, 2018
National Institute of Mental Health (NIMH)
Information provided by (Responsible Party):
Washington University School of Medicine

February 2, 2009
February 3, 2009
August 8, 2016
February 28, 2018
February 28, 2018
September 2007
May 2013   (Final data collection date for primary outcome measure)
Change of Beck Depression Inventory-II Scores Over 16 Weeks [ Time Frame: Measured at Baseline and 16 Weeks ]
Beck Depression Inventory-II (BDI) scores 0-63, minimum score =0, maximum score =63, Higher scores represent worse outcome. Baseline scores are compared to scores after treatment.
Treatment of major depressive disorder (MDD) (acute phase) and prevention of MDD recurrence (maintenance phase) [ Time Frame: Measured over 40 weeks ]
Complete list of historical versions of study NCT00834652 on Archive Site
Not Provided
  • Insulin resistance (IR), glycemic control, anthropometrics and body composition, and cortisol levels [ Time Frame: Measured over 40 weeks ]
  • Value of reducing IR for predicting reduction in depression symptoms and time-to-recurrence (TTR) [ Time Frame: Measured over 40 weeks ]
  • Sustained IR reduction during the depression-free interval following treatment [ Time Frame: Measured over 40 weeks ]
Not Provided
Not Provided
Adding an Insulin-Sensitizing Medication to Depression Treatment for People Who Are Depressed and Overweight
Improving Depression Treatment Outcomes With an Insulin-Sensitizing Agent
This study will determine whether the drug metformin improves the effects of traditional antidepressant medications in people who are overweight.

Current depression treatments are not effective for approximately one-half of overweight people, and depression eventually returns in approximately one-third of those overweight people whose initial treatment is effective. One possible reason for these treatment failures is that overweight people often experience a condition called insulin resistance (IR), which can lead to type 2 diabetes, an associated disease that might also affect depression treatment. IR results in elevated blood sugar levels that may interfere with medications used to treat depression. Metformin, a medication commonly used to treat diabetes, reduces blood sugar levels. This study will examine whether taking metformin with the antidepressant medication sertraline will enhance the effectiveness of sertraline in people who are overweight and depressed.

Participation in this study will last a total of 16 weeks and will include baseline testing and ten scheduled study visits. Participants will be randomly assigned to receive either sertraline and metformin or sertraline and placebo on a daily basis. The baseline visit will include the following tests and measures: an electrocardiogram (EKG), which will measure the electrical activity in the heart; an oral glucose tolerance test (OGTT), which will measure how a person's body breaks down glucose; a blood test, which will measure lipids, hemoglobin A1C, and other cardiometabolic risk factors; a dual energy x-ray absorptimetry (DEXA) scan, which will measure body fat; a pregnancy test for women; measurements of vital signs, height, weight, waist-to-hip ratio, and waist circumference; and questionnaires concerning health, medication use, physical activity, diet, and mood. Some of the questionnaires will be administered through interviews with a researcher. During the study visits, which will occur every 2 weeks, participants will complete questionnaires, unused medication will be collected, and new medication will be handed out. At Week 8, participants will provide an additional blood sample by finger stick.

Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Drug: Sertraline
    50 mg once a day, which may be increased to 200 mg once a day
    Other Name: Zoloft
  • Drug: Metformin
    Starting dose of 500 mg daily and increasing by 500 mg every 2 weeks to a total of 2,000 mg daily
  • Experimental: 1
    Participants will receive sertraline and metformin.
    • Drug: Sertraline
    • Drug: Metformin
  • Placebo Comparator: 2
    Participants will receive sertraline and placebo.
    Intervention: Drug: Sertraline
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
May 2013
May 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Body mass index (BMI) greater than 28.7
  • Positive screening for depression
  • Must live within 100 miles of the St. Louis metropolitan area

Exclusion Criteria:

  • Pregnant or breastfeeding
  • Known hypersensitivity to sertraline or metformin
  • Recent history of heart attack or unstable heart disease
  • Severe liver disease or kidney impairment, defined by a serum creatine level above 3 mg/dL
  • Psychiatric disorder thought to affect management, such as schizophrenia, or alcohol or drug dependence
Sexes Eligible for Study: All
20 Years to 60 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
United States
R01MH081150( U.S. NIH Grant/Contract )
R01MH081150 ( U.S. NIH Grant/Contract )
Not Provided
Not Provided
Washington University School of Medicine
Washington University School of Medicine
National Institute of Mental Health (NIMH)
Principal Investigator: Patrick J. Lustman, PhD Washington University School of Medicine
Washington University School of Medicine
January 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP